Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 89 of 487 for:    colon cancer AND resection

BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer (BASE HSP110)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02458664
Recruitment Status : Unknown
Verified November 2015 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was:  Active, not recruiting
First Posted : June 1, 2015
Last Update Posted : December 2, 2015
Sponsor:
Collaborator:
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

We collect prospectively and retrospectively, patients' demographic, pathological, surgical, therapeutic and prognosis informations in a database. After patient's consent to collect tumoural samples of their colorectal cancer after resection.

We will then be able to evaluate the impact of HSP110, a chaperon protein, on their prognosis. Other proteins (to be determined) will also be study, after.


Condition or disease Intervention/treatment
Rectum Cancer Cancer of Colon Genetic: Genetic analysis on tumor kept in tumor bank

Detailed Description:
To investigate the importance of HSP110DE9 as a prognostic marker for colorectal cancer, we will analyze genotyping fluorescence quantitative RT-PCR and / or immunomarquage the presence of this mutant in a large cohort of patients (more than 2000 patients had or having a colorectal cancer). All patients have been or will be made in general and digestive surgery department at Saint-Antoine hospital. Tumor fragments samples were or will be made on their tumor and keep it in the tumor bank of the Saint-Antoine hospital. All patients reported their no objection to the use of these tumor fragments for research purposes. A database will be built and correlated with the tumor fragments. This project is intended that the constitution of a clinical database including prognostic so that we make discoveries on HSP110DE9 or other molecular biology to discover markers can be correlated with clinical data. In the absence of other studies on the subject, with no real knowledge of the prognostic impact of this mutant, we cannot provide an effective computation. We therefore propose to make a database of 2000 patients retrospectively and prospectively to obtain statistical results valid and powerful.

Layout table for study information
Study Type : Observational
Actual Enrollment : 597 participants
Observational Model: Cohort
Official Title: BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer
Study Start Date : November 2013
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : November 2018

Group/Cohort Intervention/treatment
Colo-rectal cancer
All patients undergoing curative colorectal cancer in general and digestive surgery department at Saint-Antoine hospital
Genetic: Genetic analysis on tumor kept in tumor bank



Primary Outcome Measures :
  1. Recurrence free survival and Recurrence free survival after resection of the colon cancer [ Time Frame: End of follow up : at least 3 years ]
    3 years for prospective patients, more for retrospective patients


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: End of follow up : at least 3 years ]
    3 years for prospective patients, more for retrospective patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients, male or female, over 18 years, undergoing curative colorectal resection
Criteria

Inclusion Criteria:

  • All patients undergoing curative colorectal cancer in general and digestive surgery department at Saint-Antoine hospital.
  • Patients reporting their non-opposition to the use of tissue samples taken from their specimen for research purposes.

Exclusion Criteria:

  • Patients who did not report their non-opposition to the use of tissue samples taken from their specimen for research purposes.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02458664


Locations
Layout table for location information
France
Department of Digestive Surgery, Hôpital Saint-Antoine
Paris, France, 75012
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02458664    
Other Study ID Numbers: NI12029
2013-A01080-45 ( Other Grant/Funding Number: N° ID RCB )
First Posted: June 1, 2015    Key Record Dates
Last Update Posted: December 2, 2015
Last Verified: November 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Rectal Neoplasms
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases